Published in AIDS on October 22, 1998
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
The second wave will drown us. Am J Public Health (2003) 2.17
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 2.03
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev (2001) 1.49
HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog (2010) 1.47
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect (2001) 1.27
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol (2009) 1.11
Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS One (2008) 1.07
Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect (1999) 1.06
Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol (2009) 1.04
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS (2006) 1.01
HIV infection of the male genital tract--consequences for sexual transmission and reproduction. Int J Androl (2009) 1.01
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J Acquir Immune Defic Syndr (2012) 0.97
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob Agents Chemother (2001) 0.95
Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo. Am J Pathol (2011) 0.94
Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses. J Virol (2001) 0.93
Genital tract sequestration of SIV following acute infection. PLoS Pathog (2011) 0.90
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet (2014) 0.86
Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr (2010) 0.82
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother (2004) 0.80
HIV in semen: still more to be learned. AIDS Res Ther (2005) 0.80
Cerebrospinal fluid can be used for HIV genotyping when it fails in blood. Arq Neuropsiquiatr (2014) 0.78
Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma. Antimicrob Agents Chemother (2001) 0.76
Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response. Adv Virol (2012) 0.76
HIV Trafficking Between Blood and Semen During Early Untreated HIV Infection. J Acquir Immune Defic Syndr (2017) 0.75
Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy. Sex Transm Infect (1999) 0.75
No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men. J Virol (2017) 0.75
Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A (1992) 16.64
Functional mapping of the human visual cortex by magnetic resonance imaging. Science (1991) 6.93
Sexual transmission of HIV. N Engl J Med (1997) 6.84
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol (1989) 4.48
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
The microbicidal mechanisms of human neutrophils and eosinophils. Rev Infect Dis (1981) 3.29
Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis (1999) 3.12
Mechanism of the luminol-dependent chemiluminescence of human neutrophils. J Immunol (1982) 3.11
Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol (1993) 2.94
Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA (1995) 2.71
Preventing sexual transmission of HIV--new ideas from sub-Saharan Africa. N Engl J Med (2000) 2.67
Sexual transmission of HIV: infectiousness and prevention. AIDS (1999) 2.59
Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS (1997) 2.51
Bacterial adaptation to oxidative stress: implications for pathogenesis and interaction with phagocytic cells. FASEB J (1989) 2.47
Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Infect (2004) 2.43
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. Mol Microbiol (1998) 2.33
Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med (1981) 2.31
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 2.15
Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med (1990) 2.14
Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods (1996) 2.12
Response of Pseudomonas aeruginosa to pyocyanin: mechanisms of resistance, antioxidant defenses, and demonstration of a manganese-cofactored superoxide dismutase. Infect Immun (1992) 2.09
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS (2001) 2.08
Closed reduction and percutaneous pinning of fractures of the proximal phalanx. J Hand Surg Br (2001) 2.07
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest (1994) 1.93
Qualitative and quantitative evaluation of six algorithms for correcting intensity nonuniformity effects. Neuroimage (2001) 1.90
Brain parenchyma motion: measurement with cine echo-planar MR imaging. Radiology (1992) 1.90
Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis (2000) 1.89
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
Gonococcal infection: a model of molecular pathogenesis. N Engl J Med (1985) 1.82
Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J Exp Med (1994) 1.80
Sexually transmitted diseases in the People's Republic of China in Y2K: back to the future. Sex Transm Dis (2000) 1.80
Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry (1996) 1.77
The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS (1999) 1.76
Laparoscopic complications in markedly obese urologic patients (a multi-institutional review) Urology (1996) 1.75
Acquiring simultaneous EEG and functional MRI. Clin Neurophysiol (2000) 1.75
Immune response and vaccine efficiency. Vaccine (1998) 1.74
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
Free radicals and phagocytic cells. FASEB J (1995) 1.65
Chancroid, primary syphilis, genital herpes, and lymphogranuloma venereum in Antananarivo, Madagascar. J Infect Dis (1999) 1.64
Serum sensitivity of Neisseria gonorrhoeae: the role of lipopolysaccharide. J Infect Dis (1984) 1.64
A new deal in HIV prevention: lessons from the global approach. Ann Intern Med (1994) 1.63
Adequacy of fellowship training: results of a survey of recently graduated fellows. Clin Infect Dis (2001) 1.63
Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community. J Infect Dis (1999) 1.62
Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol (2000) 1.60
Serum IgD and IgE concentrations in immunodeficiency diseases. J Clin Invest (1975) 1.57
A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS (2001) 1.56
Recurrence of group B streptococcal infection. J Pediatr (1976) 1.48
Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. J Clin Microbiol (1997) 1.45
Primary HIV infection--a public health opportunity. Am J Public Health (1997) 1.44
Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis (1998) 1.42
Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS (1994) 1.38
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med (2006) 1.38
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Effects of H2O2-producing lactobacilli on Neisseria gonorrhoeae growth and catalase activity. J Infect Dis (1994) 1.38
Management of vaginal discharge in women treated at a Jamaican sexually transmitted disease clinic: use of diagnostic algorithms versus laboratory testing. Clin Infect Dis (1995) 1.37
Spin trapping evidence for myeloperoxidase-dependent hydroxyl radical formation by human neutrophils and monocytes. J Biol Chem (1992) 1.36
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1999) 1.32
Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis (1999) 1.32
Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology (1999) 1.28
HIV-1 viral load in blood, semen and saliva. AIDS (1997) 1.27
Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae. Am J Epidemiol (1999) 1.26
Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med (1991) 1.26
Antigenic comparison of feline coronavirus isolates: evidence for markedly different peplomer glycoproteins. J Virol (1987) 1.25
Bacteria form intracellular free radicals in response to paraquat and streptonigrin. Demonstration of the potency of hydroxyl radical. J Biol Chem (1987) 1.25